Matches in SemOpenAlex for { <https://semopenalex.org/work/W1933596914> ?p ?o ?g. }
- W1933596914 endingPage "S176" @default.
- W1933596914 startingPage "S170" @default.
- W1933596914 abstract "Background. The choice of preferred regimens for human immunodeficiency virus postexposure prophylaxis (PEP) has evolved over the last 2 decades as more data have become available regarding the safety and tolerability of newer antiretroviral drugs. We undertook a systematic review to assess the safety and efficacy of antiretroviral options for PEP to inform the World Health Organization guideline revision process. Methods. Four databases were searched up to 1 June 2014 for studies reporting outcomes associated with specific PEP regimens. Data on PEP completion and discontinuation due to adverse events was extracted and pooled estimates were obtained using random-effects meta-analyses. Results. Fifteen studies (1830 PEP initiations) provided evaluable information on 2-drug regimens (zidovudine [ZDV]- or tenofovir [TDF]-based regimens), and 10 studies (1755 initiations) provided evaluable information on the third drug, which was usually a protease inhibitor. The overall quality of the evidence was rated as very low. For the 2-drug regimen, PEP completion rates were 78.4% (95% confidence interval [CI], 66.1%–90.7%) for people receiving a TDF-based regimen and 58.8% (95% CI, 47.2%–70.4%) for a ZDV-based regimen; the rate of PEP discontinuation due to an adverse event was lower among people taking TDF-based PEP (0.3%; 95% CI, 0%–1.1%) vs a ZDV-based regimen (3.2%; 95% CI, 1.5%–4.9%). For the 3-drug comparison, PEP completion rates were highest for the TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%; 95% CI, 43.6%–98.6%; TDF+FTC+raltegravir [RAL], 74.7%; 95% CI, 41.4%–100%; TDF+FTC+ boosted darunavir [DRV/r], 93.9%; 95% CI, 90.2%–97.7%) and lowest for ZDV+ lamivudine [3TC]+LPV/r (59.1%; 95% CI, 36.2%–82.0%). Discontinuations due to adverse drug reactions were lowest for TDF+FTC+RAL (1.9%; 95% CI, 0%–3.8%) and highest for ZDV+3TC+boosted atazanavir (21.2%; 95% CI, 13.5%–30.0%). Conclusions. The findings of this review provide evidence supporting the use of coformulated TDF and 3TC/FTC as preferred backbone drugs for PEP. Choice of third drug will depend on setting; for resource-limited settings, LPV/r is a reasonable choice, pending the improved availability of better-tolerated drugs with less potential for drug–drug interactions." @default.
- W1933596914 created "2016-06-24" @default.
- W1933596914 creator A5004047139 @default.
- W1933596914 creator A5011457653 @default.
- W1933596914 creator A5025150770 @default.
- W1933596914 creator A5028339815 @default.
- W1933596914 creator A5028875922 @default.
- W1933596914 creator A5040183894 @default.
- W1933596914 creator A5046888637 @default.
- W1933596914 creator A5059371192 @default.
- W1933596914 creator A5075535479 @default.
- W1933596914 creator A5089501133 @default.
- W1933596914 date "2015-05-13" @default.
- W1933596914 modified "2023-10-10" @default.
- W1933596914 title "Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review" @default.
- W1933596914 cites W184261913 @default.
- W1933596914 cites W1870062879 @default.
- W1933596914 cites W1910280141 @default.
- W1933596914 cites W1975431536 @default.
- W1933596914 cites W1979680108 @default.
- W1933596914 cites W1989272012 @default.
- W1933596914 cites W1989467621 @default.
- W1933596914 cites W1995226511 @default.
- W1933596914 cites W1998505222 @default.
- W1933596914 cites W1998564612 @default.
- W1933596914 cites W2004331835 @default.
- W1933596914 cites W2005060361 @default.
- W1933596914 cites W2019615739 @default.
- W1933596914 cites W2023870992 @default.
- W1933596914 cites W2029727263 @default.
- W1933596914 cites W2030223911 @default.
- W1933596914 cites W2035436497 @default.
- W1933596914 cites W2045407291 @default.
- W1933596914 cites W2048481605 @default.
- W1933596914 cites W2049519861 @default.
- W1933596914 cites W2060592185 @default.
- W1933596914 cites W2067486253 @default.
- W1933596914 cites W2079558133 @default.
- W1933596914 cites W2081911995 @default.
- W1933596914 cites W2092923243 @default.
- W1933596914 cites W2102180513 @default.
- W1933596914 cites W2117057469 @default.
- W1933596914 cites W2121551893 @default.
- W1933596914 cites W2121737909 @default.
- W1933596914 cites W2134236426 @default.
- W1933596914 cites W2137287128 @default.
- W1933596914 cites W2148403108 @default.
- W1933596914 cites W2162714184 @default.
- W1933596914 cites W2168251450 @default.
- W1933596914 cites W2317983531 @default.
- W1933596914 cites W2327439176 @default.
- W1933596914 doi "https://doi.org/10.1093/cid/civ092" @default.
- W1933596914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25972499" @default.
- W1933596914 hasPublicationYear "2015" @default.
- W1933596914 type Work @default.
- W1933596914 sameAs 1933596914 @default.
- W1933596914 citedByCount "38" @default.
- W1933596914 countsByYear W19335969142015 @default.
- W1933596914 countsByYear W19335969142016 @default.
- W1933596914 countsByYear W19335969142017 @default.
- W1933596914 countsByYear W19335969142018 @default.
- W1933596914 countsByYear W19335969142019 @default.
- W1933596914 countsByYear W19335969142020 @default.
- W1933596914 countsByYear W19335969142021 @default.
- W1933596914 countsByYear W19335969142022 @default.
- W1933596914 countsByYear W19335969142023 @default.
- W1933596914 crossrefType "journal-article" @default.
- W1933596914 hasAuthorship W1933596914A5004047139 @default.
- W1933596914 hasAuthorship W1933596914A5011457653 @default.
- W1933596914 hasAuthorship W1933596914A5025150770 @default.
- W1933596914 hasAuthorship W1933596914A5028339815 @default.
- W1933596914 hasAuthorship W1933596914A5028875922 @default.
- W1933596914 hasAuthorship W1933596914A5040183894 @default.
- W1933596914 hasAuthorship W1933596914A5046888637 @default.
- W1933596914 hasAuthorship W1933596914A5059371192 @default.
- W1933596914 hasAuthorship W1933596914A5075535479 @default.
- W1933596914 hasAuthorship W1933596914A5089501133 @default.
- W1933596914 hasBestOaLocation W19335969142 @default.
- W1933596914 hasConcept C126322002 @default.
- W1933596914 hasConcept C142462285 @default.
- W1933596914 hasConcept C142724271 @default.
- W1933596914 hasConcept C197934379 @default.
- W1933596914 hasConcept C203014093 @default.
- W1933596914 hasConcept C2777182164 @default.
- W1933596914 hasConcept C2778375690 @default.
- W1933596914 hasConcept C2778715236 @default.
- W1933596914 hasConcept C2779298103 @default.
- W1933596914 hasConcept C2779778239 @default.
- W1933596914 hasConcept C2780182762 @default.
- W1933596914 hasConcept C2780216070 @default.
- W1933596914 hasConcept C2780727368 @default.
- W1933596914 hasConcept C2781413609 @default.
- W1933596914 hasConcept C2993143319 @default.
- W1933596914 hasConcept C3013748606 @default.
- W1933596914 hasConcept C71924100 @default.
- W1933596914 hasConceptScore W1933596914C126322002 @default.
- W1933596914 hasConceptScore W1933596914C142462285 @default.
- W1933596914 hasConceptScore W1933596914C142724271 @default.